公开(公告)号：US20230130372A1

公开(公告)日：2023-04-27

申请号：US17757510

申请日：2020-12-17

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  THE GEORGE WASHINGTON UNIVERSITY

Inventor： Ningyan ZHANG ,  Zhiqiang AN ,  Hui DENG ,  Xiujie SUN ,  Rong LI

IPC: C07K16/28 ,  C12N15/63 ,  A61P35/00

Abstract: The present disclosure relates to antibodies binding to tumor discoidin domain receptor 1 (DDR1) and the uses of the antibodies in detecting and treating cancer. Thus, in one aspect, the present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to DDR1. In certain embodiments, the antibody or antigen-binding fragment, when bound to DDR1, modulates the activity of DDR1, i.e., suppresses DDR1.

公开(公告)号：US20230235078A1

公开(公告)日：2023-07-27

申请号：US18176072

申请日：2023-02-28

Applicant: The BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  THE GEORGE WASHINGTON UNIVERSITY

Inventor： Ningyan ZHANG ,  Zhiqiang AN ,  Hui DENG ,  Xiujie SUN ,  Rong LI

IPC: C07K16/28 ,  C12N15/63 ,  A61P35/00

CPC classification number: C07K16/2896 ,  C12N15/63 ,  A61P35/00 ,  C07K2317/20 ,  C07K2317/565

Abstract: The present disclosure relates to antibodies binding to tumor discoidin domain receptor 1 (DDR1) and the uses of the antibodies in detecting and treating cancer.

公开(公告)号：US20240383999A1

公开(公告)日：2024-11-21

申请号：US17995214

申请日：2021-04-01

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Ningyan ZHANG ,  Zhiqiang AN ,  Zhiqiang KU ,  Hui DENG ,  Lingegowda S MANGALA ,  Anil K. SOOD

IPC: C07K16/28 ,  A61K39/00

Abstract: Provided herein are anti-CD5L monoclonal antibodies. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer.

公开(公告)号：US20220056124A1

公开(公告)日：2022-02-24

申请号：US17273538

申请日：2019-09-05

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Ningyan ZHANG ,  Dawei BU ,  Zhiqiang AN ,  Hui DENG ,  Philipp E. SCHERER

IPC: C07K16/26 ,  A61P35/00

Abstract: Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alphas chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.